Naijian Ge

Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)

Hai‐Dong Zhu, Hai-Liang Li, Mingsheng Huang et al. · Signal Transduction and Targeted Therapy · 2023 · 283 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study

Zhi‐Cheng Jin, Jian-Jia Chen, Xiaoli Zhu et al. · EClinicalMedicine · 2024 · 143 citations · Full text

Medicine, Oncology, Pharmacology +17

Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study

Zhi‐Cheng Jin, Bin‐Yan Zhong, Jian-Jia Chen et al. · European Radiology · 2023 · 88 citations · Full text

Medicine, Oncology, Pharmacology +14

Detection of Circulating Tumor Cells in Hepatocellular Carcinoma Using Antibodies against Asialoglycoprotein Receptor, Carbamoyl Phosphate Synthetase 1 and Pan-Cytokeratin

Jun Li, Lei Chen, Xiaofeng Zhang et al. · PLoS ONE · 2014 · 65 citations · Full text

Medicine, Cancer Biology, Oncology +16

Selective Tumor Cell Inhibition Effect of Ni–Ti Layered Double Hydroxides Thin Films Driven by the Reversed pH Gradients of Tumor Cells

Donghui Wang, Naijian Ge, Jinhua Li et al. · ACS Applied Materials & Interfaces · 2015 · 55 citations

Natural Sciences, Materials Science, Oncology +13